Climb Bio, Inc.
CLYM · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.01 | 0.00 | 0.10 |
| FCF Yield | -13.39% | -18.75% | -4.74% | -2.21% |
| EV / EBITDA | -7.16 | -2.34 | -2.73 | -16.62 |
| Quality | ||||
| ROIC | -5.72% | -11.86% | -5.13% | -5.36% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 1.29 | 0.74 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 27.27% | -179.55% | 26.92% | -1,032.68% |
| Safety | ||||
| Net Debt / EBITDA | 2.55 | 1.24 | 7.95 | 12.45 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,240.53 | 0.00 | 0.00 | 0.00 |